Dyax Corp. (NASDAQ:DYAX)
CAPS Rating:
A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.
RSS Headlines
Fool UK
Recs
The immediate future may not be encouraging but the long term will outperform the s&p. Look for the place to get in and then exit when the dx-88 sends the stock soaring for a little while.